WS #4003

The data dump reveals several high-signal developments with immediate market implications. Most notably, SpaceX has officially filed for its IPO, with Bloomberg and Reuters reporting the submission of registration documents. This event, dubbed 'Project Apex,' is poised to be one of the largest public offerings in history, with a potential valuation reaching $1.75 trillion, driven by the integration of xAI and the profitability of Starlink. This could significantly impact the aerospace and tech sectors, potentially affecting related stocks and market sentiment. In the pharmaceutical sector, Eli Lilly received FDA approval for its new daily weight loss pill, Foundayo, through an expedited review process. This development pressures competitor Novo Nordisk and could influence healthcare and biotech stocks. Concurrently, geopolitical tensions persist with Iran's President Pezeshkian issuing a letter to the American public, denying enmity but questioning the war's motives, while President Trump claims Iran seeks a ceasefire contingent on reopening the Strait of Hormuz. These statements, coupled with reports of U.S. troops discussing deployments, suggest ongoing volatility in energy markets, with oil prices potentially averaging $100 for the rest of 2026 according to SEB analysis. Corporate actions include Ryanair warning of potential fuel supply disruptions affecting summer operations, indicating stress in the aviation sector. Additionally, Goldman Sachs added Rheinmetall to its 'European Conviction List,' citing structural benefits from European rearmament, which could boost defense stocks. These developments, alongside routine filings and noise, highlight near-term risks in energy, aerospace, pharmaceuticals, and defense.